Incidence and Temporal Trend of Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis

Nannan Wang; Xinyu Chen; Zhuolu Hao; Jia Guo; Xuwen Wang; Xijing Zhu; Honggang Yi; Qingliang Wang; Shaowen Tang

doi:10.1155/2022/8266878

Incidence and Temporal Trend of Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis

J Trop Med. 2022 Oct 4:2022:8266878. doi: 10.1155/2022/8266878. eCollection 2022.

Authors

Nannan Wang¹, Xinyu Chen¹, Zhuolu Hao¹, Jia Guo¹, Xuwen Wang², Xijing Zhu³, Honggang Yi¹, Qingliang Wang⁴, Shaowen Tang¹

Affiliations

¹ Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.
² School of Pharmacy, Nanjing Medical University, Nanjing, China.
³ First School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
⁴ Department of Medical Affairs, Qilu Hospital of Shandong University, Jinan, China.

Abstract

Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards were followed, and the protocol was registered in PROSPERO (CRD42020200077). Five electronic databases were searched to identify eligible studies published between 1990 and 2022. Search terms included anti-TB treatment and drug-induced liver injury. Studies that reported the incidence of ATLI or provided sufficient data to calculate the incidence of ATLI were included, and duplicate studies were excluded. Meta-analysis was conducted on the basis of logit-transformed metrics for the incidence of ATLI with 95% confidence intervals (CIs), followed by a predefined subgroup meta-analysis. Temporal trend analyses were performed to describe the change in pooled incidence over time. A random effects metaregression was conducted to explore the source of heterogeneity. All statistical analyses were carried out using R 4.0.1.

Results: A total of 160 studies from 156 records with 116147 patients were included in the meta-analysis. Based on the random effects model, the pooled incidence of ATLI was 11.50% (95% CI: 10.10%-12.97%) and showed an upward trend over time (P < 0.001). Patients who received first-line anti-TB drugs, patients in South America, and patients with hepatitis B and C virus coinfection had a higher incidence of ATLI (13.66%, 18.16%, and 39.19%, respectively). Sensitivity analyses also confirmed this robust incidence after the exclusion of some studies. The metaregression showed that different anti-TB regimens and geographical regions were important explanatory factors of the heterogeneity between studies.

Conclusions: The present systematic review provided a basis for estimating the incidence of ATLI worldwide, which varied among patients with different anti-TB regimens in different geographical regions and with different coinfections and had an upward trend. Regular liver function monitoring is imperative for patient safety during the anti-TB treatment course.